西塔
人类白细胞抗原
生物
癌症研究
微阵列分析技术
黑色素瘤
基因表达
免疫学
T细胞
基因
抗原
遗传学
MHC II级
免疫系统
作者
T. Huibertus van Essen,Sake I. van Pelt,Inge H. G. Bronkhorst,Mieke Versluis,Fariba Némati,Cécile Laurent,Grégorius P. M. Luyten,Thorbald van Hall,Peter J. van den Elsen,Pieter A. van der Velden,Didier Decaudin,Martine J. Jager
出处
期刊:PLOS ONE
[Public Library of Science]
日期:2016-10-20
卷期号:11 (10): e0164292-e0164292
被引量:62
标识
DOI:10.1371/journal.pone.0164292
摘要
Introduction Uveal melanoma (UM) with an inflammatory phenotype, characterized by infiltrating leukocytes and increased human leukocyte antigen (HLA) expression, carry an increased risk of death due to metastases. These tumors should be ideal for T-cell based therapies, yet it is not clear why prognostically-infaust tumors have a high HLA expression. We set out to determine whether the level of HLA molecules in UM is associated with other genetic factors, HLA transcriptional regulators, or microenvironmental factors. Methods 28 enucleated UM were used to study HLA class I and II expression, and several regulators of HLA by immunohistochemistry, PCR microarray, qPCR and chromosome SNP-array. Fresh tumor samples of eight primary UM and four metastases were compared to their corresponding xenograft in SCID mice, using a PCR microarray and SNP array. Results Increased expression levels of HLA class I and II showed no dosage effect of chromosome 6p, but, as expected, were associated with monosomy of chromosome 3. Increased HLA class I and II protein levels were positively associated with their gene expression and with raised levels of the peptide-loading gene TAP1, and HLA transcriptional regulators IRF1, IRF8, CIITA, and NLRC5, revealing a higher transcriptional activity in prognostically-bad tumors. Implantation of fresh human tumor samples into SCID mice led to a loss of infiltrating leukocytes, and to a decreased expression of HLA class I and II genes, and their regulators. Conclusion Our data provides evidence for a proper functioning HLA regulatory system in UM, offering a target for T-cell based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI